Tauriga Sciences Inc. Introduces First Cannabis Complements Product in Colorado
DENVER, July 28, 2014 (GLOBE NEWSWIRE) — Tauriga Sciences Inc. (OTCQB:TAUG) or (“Tauriga” or “the Company”), a diversified life sciences company, is introducing the first supplement in its Cannabis Complements line of dietary supplements and natural wellness products to the Colorado market. Tauriga’s Cannabis Complements products do not contain cannabis oil but address health and experiential effects relevant to cannabis users as well as to the general public. The first product, Satietiva, is a natural, amino-acid-based supplement for appetite control. Its proprietary formulation is based on licensed, patented technology and contains only “GRAS” ingredients (the U.S. Food and Drug Administration’s designation for ingredients that are “Generally Recognized as Safe”) to support the specific neurotransmitter activity associated with appetite control, independent of the cause of increased appetite. Tauriga is partnering with The Mary Jane Group (OTCBB:MJMJ) to introduce Satietiva to guests of The Adagio, a historic Victorian bed & breakfast (“bud & breakfast”) in Denver owned and operated by The Mary Jane Group.
Tauriga’s Chairman & CEO, Dr. Stella M. Sung states, “We are delighted to introduce Satietiva to the Colorado market. Satietiva is the first of many products in our Cannabis Complements natural wellness line. Other products will include IndiCalm, a natural dietary supplement to reduce anxiety; ClearNase, a natural and effective non-drug decongestant with neither stimulant nor drowsiness effects; and Endocannabinoid Omega-3 Support, a premium, potent, pure and palatable fish oil supplement to support the efficient function of the endocannaniboid system. Moreover, we believe The Adagio will be an ideal test market site for the important and growing Colorado demographic.”
Joel Schneider, CEO of The Mary Jane Group, adds, “Tauriga’s products are a perfect fit for The Adagio, the flagship property in our hospitality business. We look forward to introducing additional Tauriga products to our guests and to expanding our relationship with Tauriga as we continue to provide Colorado-based businesses with marketing, advertising and entertainment services geared toward medical marijuana patients and recreational marijuana users.”
In addition to introducing the non-cannabis-containing dietary supplements to the Colorado market, Tauriga, through its recently acquired subsidiary, Honeywood, is actively evaluating near-term options for expanding operations and production of cannabis-containing products into Colorado. These products include the established Doc Green’s brand of topical cannabis cream, as well as new products such as Vapura, a medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (OTCQB:TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 10, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company’s corporate website at www.tauriga.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.